Analyzing BR Biopharma (BRBI) & Its Peers

BR Biopharma (NASDAQ:BRBI) is one of 1,747 public companies in the “Capital Markets” industry, but how does it weigh in compared to its rivals? We will compare BR Biopharma to similar companies based on the strength of its profitability, valuation, risk, earnings, dividends, institutional ownership and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for BR Biopharma and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BR Biopharma	1	0	0	0	1.00
BR Biopharma Competitors	5340	19683	21888	612	2.37

As a group, “Capital Markets” companies have a potential upside of 25.01%. Given BR Biopharma’s rivals stronger consensus rating and higher possible upside, analysts clearly believe BR Biopharma has less favorable growth aspects than its rivals.

Dividends

BR Biopharma pays an annual dividend of $0.42 per share and has a dividend yield of 3.8%. BR Biopharma pays out 525.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Capital Markets” companies pay a dividend yield of 3.1% and pay out 30.8% of their earnings in the form of a dividend.

Insider & Institutional Ownership

30.5% of shares of all “Capital Markets” companies are held by institutional investors. 12.9% of shares of all “Capital Markets” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares BR Biopharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BR Biopharma	N/A	N/A	N/A
BR Biopharma Competitors	267.77%	78.34%	3.56%

Valuation and Earnings

This table compares BR Biopharma and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BR Biopharma	$2.23 billion	$31.36 million	136.50
BR Biopharma Competitors	$2.48 billion	$397.49 million	9.68

BR Biopharma’s rivals have higher revenue and earnings than BR Biopharma. BR Biopharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

BR Biopharma rivals beat BR Biopharma on 12 of the 14 factors compared.

BR Biopharma Company Profile

BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.